Brief: Neurosense Ends Its At-The-Market Equity Offering Program

Neurosense Therapeutics

02/10/2023 14:48

Oct 2 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE ENDS ITS AT-THE-MARKET EQUITY OFFERING PROGRAM:
COMPANY IS FULLY FUNDED BEYOND CLINICAL PHASE 2B ALS RESULTS
    * NEUROSENSE THERAPEUTICS LTD - TOPLINE CLINICAL DATA FROM
ALS
PHASE 2B PARADIGM TRIAL OF PRIMEC COMBINATION THERAPY IS
EXPECTED Q4 2023
    * NEUROSENSE THERAPEUTICS LTD - COMPANY IS FULLY FUNDED INTO
Q2
2024

Source text for Eikon:  ID:nPn3DLvNZa 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))